Journal
ADVANCED SCIENCE
Volume -, Issue -, Pages -Publisher
WILEY
DOI: 10.1002/advs.202301120
Keywords
HD KI-140Q mice; intravenous injection; lysosome; mini-intrabody; mutant huntingtin; SM3; stereotaxic injection
Ask authors/readers for more resources
Researchers designed a peptide that specifically binds mutant huntingtin and its aggregates, and brings them into lysosomes for degradation, thereby improving neuropathology and behavioral abnormalities in HD KI-140Q mice.
Accumulation of misfolded proteins leads to many neurodegenerative diseases that can be treated by lowering or removing mutant proteins. Huntington's disease (HD) is characterized by the intracellular accumulation of mutant huntingtin (mHTT) that can be soluble and aggregated in the central nervous system and causes neuronal damage and death. Here, an intracellular antibody (intrabody) fragment is generated that can specifically bind mHTT and link to the lysosome for degradation. It is found that delivery of this peptide by either brain injection or intravenous administration can efficiently clear the soluble and aggregated mHTT by activating the lysosomal degradation pathway, resulting in amelioration of gliosis and dyskinesia in HD knock-in (KI-140Q) mice. These findings suggest that the small intrabody peptide linked to lysosomes can effectively lower mutant proteins and provide a new approach for treating neurodegenerative diseases that are caused by the accumulation of mutant proteins. The authors designed a peptide that specifically binds mutant huntingtin and its aggregates, and brings them into lysosomes for degradation, thereby improving neuropathology and behavioral abnormalities in HD KI-140Q mice.image
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available